Inside the AI BioHub: Meet the Inaugural Cohort
Read the blogLabCentral Blog
Earlier this year, in partnership with our partners, C10 Labs, we put out a call to founders building at the intersection of artificial intelligence (AI) and life sciences to join the second cohort of the groundbreaking AI BioHub accelerator program. The call brought in a flood of inspiring and compelling applications from entrepreneurs working on new therapies, platforms and more. From that pool, we selected 16 teams who began the program on March 19th.
Designed for AI-First Biotech
Since graduating from the program a few months ago, teams from the first cohort have raised over $8M in pre-seed funding and created over 26 jobs for the Commonwealth. Building on the success of the inaugural cohort in 2025, this new group of early-stage companies represents the continued evolution of a program purpose-built to support TechBio entrepreneurs at critical stages of technical and business development.
In partnership with C10 labs, the program integrates both scientific and company-building support, ensuring teams can move quickly to validation. Over the course of ten weeks, the cohort members are participating in weekly programming, covering topics ranging from the Business of Biotech to Generative AI and Machine Learning Operations. In addition to curated curriculum, participants have access to wet lab space at LabCentral, including specialized instrumentation for high-speed cell sorting and automated liquid handling, in addition to the other equipment LabCentral offers. They also receive expert AI support from C10’s AI Fellows, as well as individualized mentorship from industry leaders.
We’re enormously grateful to the Massachusetts Technology Collaborative for the Sector Spark grant that’s making this program possible as part of their overall AI initiative, and to the participating entrepreneurs.
Introducing the Second Cohort
We’re proud to introduce the 16 participating startups! Each brings a unique approach to advancing human health by utilizing AI.
Adelle Diagnostics is building an AI-powered molecular diagnostics platform to transform dementia care by enabling precise prediction of treatment response, starting with NPH.
Alces Bioworks uses generative AI and lab automation to rapidly design and make superior affinity reagents we call Alceins™.
AracodeX is building an AI-enabled programmable molecular infrastructure to control how drugs are delivered and activated in the body for next-generation drug conjugates and targeted therapeutics.
Causal Data AI generates experimental ground truth data proving whether drugs work in human tissue. Using patient organoids, active perturbation, and causal AI models, the platform validates drug mechanisms before clinical trials—de-risking pharma's billion-dollar development decisions.
Collixion Tx
Collixion TX is developing therapies that prevent cancer relapse by targeting how tumors adapt to treatment, starting with ovarian cancer.
Find.Bio is reverse engineering biology, using AI and large-scale molecular simulations to discover drugs, targets, and predict toxicity.
Harmonia Therapeutics
Harmonia Therapeutics engineers logic-gated ADCs that sense and respond to their extracellular and intracellular environment to activate exclusively in cancer cells, dramatically improving safety and efficacy for treatment-resistant cancers.
HarborSite uses large gene insertions by AI-designed recombinases to treat human diseases and enhance biological systems.
HeraHealth is an AI-driven SaMD that accurately quantifies postpartum blood loss in real time to provide data-driven support so clinicians can identify hemorrhage sooner and expedite treatment.
Hiba Therapeutics is an AI-enabled programmable immunotherapy platform that harnesses the power bystander T cells to specifically target and attack cancer cells with exquisite safety and efficacy.
Intertwined Biosciences is harnessing the results of evolution with AI-native discovery to design regenerative therapeutics.
Meteor Biosciences is developing a new class of bioenergetic medicines designed through its metabolic intelligence platform to reverse complex disease by restoring healthy metabolic function in diseased cells.
ScriptBio AI
ScriptBio AI is an AI-driven platform discovering causal gene targets in aging-related disease and engineering stem cells to correct them.
Seedbox Labs is building the first reusable, AI-powered, clinical-grade at-home platform for WHO-standard semen analysis and longitudinal male fertility tracking.
tBrexa Bio is an AI/ML-enabled, regulatory-first CDMO bridging biologics development, manufacturing, and CMC data to reach IND readiness faster.
Tiller Therapeutics utilizes proprietary ML-driven in silico discovery and lead opt platform to identify and optimize targeted small molecule therapies with a tunable wide therapeutic index to treat solid tumors.
Looking Ahead
This program gives LabCentral and C10 Labs the opportunity to support the specific needs of AI-native biotech companies by strengthening both infrastructure and programming now and down the road.
We look forward to helping these founders along their journeys over the coming weeks and welcoming them to the LabCentral and C10 Labs communities. Stay tuned for more updates to come along the way! Are you a potential industry partner for any of these companies? Reach out to us and we’ll connect you directly with the founders. Are you interested in investing at the intersection of AI and Bio? We hope to see you at the AI BioHub Showcase for these teams this summer!
